KR20160040522A - 유리 염기 결정 - Google Patents

유리 염기 결정 Download PDF

Info

Publication number
KR20160040522A
KR20160040522A KR1020167001273A KR20167001273A KR20160040522A KR 20160040522 A KR20160040522 A KR 20160040522A KR 1020167001273 A KR1020167001273 A KR 1020167001273A KR 20167001273 A KR20167001273 A KR 20167001273A KR 20160040522 A KR20160040522 A KR 20160040522A
Authority
KR
South Korea
Prior art keywords
methyl
crystals
pyrazolo
free base
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167001273A
Other languages
English (en)
Korean (ko)
Inventor
다카시 아베
그라함 북톤
로버트 데이비스
마크 후퍼
펭 리
히데아키 마루야마
마사히로 다카수가
로렌스 피. 웨노글
유헤이 야마모토
히로노리 야마시타
Original Assignee
인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인트라-셀룰라 써래피스, 인코퍼레이티드. filed Critical 인트라-셀룰라 써래피스, 인코퍼레이티드.
Priority to KR1020217030964A priority Critical patent/KR102430126B1/ko
Publication of KR20160040522A publication Critical patent/KR20160040522A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020167001273A 2013-06-21 2014-06-20 유리 염기 결정 Ceased KR20160040522A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217030964A KR102430126B1 (ko) 2013-06-21 2014-06-20 유리 염기 결정

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US61/838,105 2013-06-21
US201361919424P 2013-12-20 2013-12-20
US61/919,424 2013-12-20
PCT/US2014/043422 WO2014205354A2 (en) 2013-06-21 2014-06-20 Free base crystals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030964A Division KR102430126B1 (ko) 2013-06-21 2014-06-20 유리 염기 결정

Publications (1)

Publication Number Publication Date
KR20160040522A true KR20160040522A (ko) 2016-04-14

Family

ID=52105535

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167001273A Ceased KR20160040522A (ko) 2013-06-21 2014-06-20 유리 염기 결정
KR1020217030964A Active KR102430126B1 (ko) 2013-06-21 2014-06-20 유리 염기 결정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217030964A Active KR102430126B1 (ko) 2013-06-21 2014-06-20 유리 염기 결정

Country Status (13)

Country Link
US (1) US9630971B2 (OSRAM)
EP (2) EP3010509B1 (OSRAM)
JP (2) JP6865036B2 (OSRAM)
KR (2) KR20160040522A (OSRAM)
CN (3) CN105658222A (OSRAM)
AU (1) AU2014284224B2 (OSRAM)
BR (1) BR112015032132B1 (OSRAM)
CA (1) CA2916393C (OSRAM)
ES (1) ES2894770T3 (OSRAM)
IL (2) IL267331B2 (OSRAM)
MX (2) MX2015017972A (OSRAM)
RU (1) RU2675851C2 (OSRAM)
WO (1) WO2014205354A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CA2916393C (en) 2013-06-21 2022-03-22 Intra-Cellular Therapies, Inc. Free base crystals
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
WO2021226407A1 (en) * 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
WO2022026417A1 (en) * 2020-07-26 2022-02-03 Intra-Cellular Therapies, Inc. Novel uses
US20240383909A1 (en) * 2021-09-03 2024-11-21 Intra-Cellular Therapies, Inc. Co-crystals
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
ES2356306T3 (es) * 2002-02-08 2011-04-06 Ono Pharmaceutical Co., Ltd. Compuestos y fármacos derivados de piperidina que contienen los compuestos como principio activo.
EP1613747A1 (en) * 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
WO2005020920A2 (en) * 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CN102153505B (zh) * 2004-09-27 2014-10-22 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
KR20120012831A (ko) * 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US20120070443A1 (en) * 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EA201170771A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011043816A1 (en) 2009-10-08 2011-04-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CA2916393C (en) 2013-06-21 2022-03-22 Intra-Cellular Therapies, Inc. Free base crystals

Also Published As

Publication number Publication date
IL267331A (en) 2019-08-29
BR112015032132B1 (pt) 2022-03-15
EP3010509B1 (en) 2021-07-28
IL243269A0 (en) 2016-02-29
CN105658222A (zh) 2016-06-08
CA2916393A1 (en) 2014-12-24
BR112015032132A2 (pt) 2017-07-25
WO2014205354A2 (en) 2014-12-24
KR20210122890A (ko) 2021-10-12
KR102430126B1 (ko) 2022-08-05
CA2916393C (en) 2022-03-22
IL243269B (en) 2019-06-30
EP3702358A1 (en) 2020-09-02
ES2894770T3 (es) 2022-02-15
JP2019189618A (ja) 2019-10-31
RU2016101630A (ru) 2017-07-26
RU2675851C2 (ru) 2018-12-25
EP3010509A4 (en) 2016-11-23
MX2020001628A (es) 2020-07-13
WO2014205354A3 (en) 2015-05-28
MX2015017972A (es) 2016-10-28
JP6865036B2 (ja) 2021-04-28
CN112851683A (zh) 2021-05-28
US9630971B2 (en) 2017-04-25
IL267331B1 (en) 2024-08-01
IL267331B2 (en) 2024-12-01
AU2014284224B2 (en) 2019-08-01
RU2016101630A3 (OSRAM) 2018-03-21
AU2014284224A1 (en) 2016-02-11
US20160145261A1 (en) 2016-05-26
JP2016523258A (ja) 2016-08-08
EP3010509A2 (en) 2016-04-27
HK1223848A1 (zh) 2017-08-11
CN110498800A (zh) 2019-11-26

Similar Documents

Publication Publication Date Title
KR102430126B1 (ko) 유리 염기 결정
JP6853794B2 (ja) 塩結晶
CN108699063A (zh) 一种芦可替尼的合成工艺
US12435093B2 (en) Free base crystals
HK40036801A (en) Process for preparing salts of a known pde1 inhibitor
HK1223848B (en) Free base crystals
HK1247191A1 (en) Salt crystals
CN116406365A (zh) 用于制备1-甲基-6-[6-R2-5-甲基-8-(甲基氨基)-4-[(3aS,6aS)-5-甲基-2,3,3a,4,6,6a-六氢吡咯并[2,3-c]吡咯-1-基]-9H-吡啶并[2,3-b]吲哚-3-基]-4-氧代-1,8-萘啶-3-甲酸盐酸盐的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190618

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201103

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210526

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210526

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201229

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190618

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210728

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210628

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210526

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201229

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20201103

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190618

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210927